The BioNTech SE ADR BNTX rallied 3.82% to $120.21 Monday, on what proved to be an all-around mixed trading session for the ...

Shares of vaccine makers moved higher early Monday following a CDC report that the U.S. was seeing a significant uptick in ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

The university filed a lawsuit against BioNTech four months ago, claiming that the company licensed vaccine technology ...

I made four predictions about the stock market in 2024. The Fed indeed cut rates in Q4, but stocks didn't jump as much as I ...

University of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine royalties, writes John George ...

The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

A third dose of COVID-19 vaccine is beneficial among older Medicare beneficiaries, regardless of prior medically attended COVID-19 diagnoses.

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...